Dr. Medical Health review

The former treatment offer is no longer a current quote

DrMedHealth’s former pricing address now opens an AI health-information site with disease information, general medical questions and a provider-search directory. It does not present an active GLP-1 purchase offer or a current semaglutide or tirzepatide price. A hospital or clinic result on a map is not an offer by DrMedHealth to prescribe medication. Do not use the older $199 or $299 figures as evidence that the same prescription program accepts new orders today. Look for a current treatment agreement identifying the actual clinical service, care partners, prescribed supply and complete charge.

The current site describes its content as educational and says it does not sell products, prescribe medicine or provide medical care. That describes the public website; it does not prove that the operating company permanently closed or explain what care an existing patient may still receive under a separate agreement. Existing patients should use the clinical and support contacts supplied with their treatment to clarify refills, continuity and billing. A directory account or information tool should not be assumed to restore a previous prescription relationship.

The FDA letter remains relevant historical context

The FDA issued warning letter 728278, to Public Health Solution LLC doing business as DrMedHealth. It identified Dr. Medical Health's website and cited false or misleading compounded semaglutide and tirzepatide claims and misbranding. The company, domain, address, and email connected the letter to this service rather than another similarly named operator. That regulatory record should remain visible even though the public-facing offer has changed, without being treated as a finding about an individual patient's current health or a separate company's product.

Earlier versions of the site removed the specific ingredient-equivalence claims cited by the FDA. Removing wording does not, by itself, establish that the agency issued a close-out or that a new treatment program is approved. Compounded drugs are not FDA-approved finished medicines, regardless of familiar active ingredients. If prescription services are offered again, ask how the company describes the actual preparation and the medical and dispensing arrangements. A changed website or an information-service label cannot supply those product-specific answers.

Earlier prices and policies are historical only

The previous catalog listed compounded semaglutide at $199 per month and tirzepatide at $299, with oral and injectable forms at the same respective amounts. It described flat pricing across doses but did not clearly define how many weeks a charge supplied. Those details are historical context, not a newly verified current purchase option. Matching an old ingredient or price in a search result does not establish that the preparation, quantity, or care terms remain available today.

The earlier service also used no-subscription marketing while its FAQ and refund policy described recurring billing and cancellation before another processed order. Dispensed medication was nonrefundable even unopened. If a new treatment offer appears, obtain its own renewal authorization, stopping deadline, and refund conditions instead of assuming that either side of the old contradiction now governs. A lower card price or an information-service subscription should not be substituted for a complete agreement covering medical care and medication.

A future decision needs identifiable clinical responsibility

Earlier GLP-1 disclosures said DrMedHealth was a technology platform rather than a practice or pharmacy and did not employ the clinicians, while leaving the actual network and dispenser unnamed. A renewed prescription offer would need those identities, along with the assigned clinician's licensure, pharmacy contact, formulation, quantity, storage, and instructions. A platform's corporate name is useful without establishing who makes an individual medical decision or dispenses the preparation a patient receives.

DrMedHealth cannot currently supply a public GLP-1 price comparison from its homepage or former pricing route. Do not transfer historical nationwide claims, oral options or medication totals to the information service. If a directory helps you find another clinician, confirm that practice’s credentials, services, fees and dispensing arrangements directly. Pregnancy planning, breastfeeding, postpartum or PCOS circumstances require appropriate clinical advice rather than an answer inferred from a general information tool. The FDA record remains relevant history, while any future treatment offer needs its own clear clinical and financial terms.